These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 34697980)

  • 21. Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.
    Simões RSQ; Rodríguez-Lázaro D
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.
    Kantarcioglu B; Iqbal O; Lewis J; Carter CA; Singh M; Lievano F; Ligocki M; Jeske W; Adiguzel C; Gerotziafas GT; Fareed J
    Clin Appl Thromb Hemost; 2022; 28():10760296211056648. PubMed ID: 35167393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants.
    Takagi A; Matsui M
    Microbiol Spectr; 2021 Dec; 9(3):e0165921. PubMed ID: 34937174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The COVID-19 pandemic: viral variants and vaccine efficacy.
    Ciotti M; Ciccozzi M; Pieri M; Bernardini S
    Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
    Zhou Z; Zhu Y; Chu M
    Front Immunol; 2022; 13():898192. PubMed ID: 35669787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics.
    Jacob JJ; John Fletcher G; Monisha Priya T; Veeraraghavan B; Mutreja A
    Indian J Med Microbiol; 2021; 39(4):417-422. PubMed ID: 34454775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study.
    Mathema B; Chen L; Chow KF; Zhao Y; Zody MC; Mediavilla JR; Cunningham MH; Composto K; Lee A; Oschwald DM; Germer S; Fennessey S; Patel K; Wilson D; Cassell A; Pascual L; Ip A; Corvelo A; Dar S; Kramer Y; Maniatis T; Perlin DS; Kreiswirth BN
    Microbiol Spectr; 2021 Dec; 9(3):e0188221. PubMed ID: 34787439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
    Smolenov I; Han HH; Li P; Baccarini C; Verhoeven C; Rockhold F; Clemens SAC; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R;
    Lancet Infect Dis; 2022 Jul; 22(7):990-1001. PubMed ID: 35447085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?
    Joshi G; Borah P; Thakur S; Sharma P; Mayank ; Poduri R
    Hum Vaccin Immunother; 2021 Dec; 17(12):4714-4740. PubMed ID: 34856868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
    Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B
    PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants.
    Li T; Luo KQ
    Int J Biol Sci; 2022; 18(12):4642-4647. PubMed ID: 35874950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
    McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM
    Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 vaccinations: The unknowns, challenges, and hopes.
    Mohamed K; Rzymski P; Islam MS; Makuku R; Mushtaq A; Khan A; Ivanovska M; Makka SA; Hashem F; Marquez L; Cseprekal O; Filgueiras IS; Fonseca DLM; Mickael E; Ling I; Arero AG; Cuschieri S; Minakova K; Rodríguez-Román E; Abarikwu SO; Faten AB; Grancini G; Cabral-Marques O; Rezaei N
    J Med Virol; 2022 Apr; 94(4):1336-1349. PubMed ID: 34845731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
    Hodgson SH; Mansatta K; Mallett G; Harris V; Emary KRW; Pollard AJ
    Lancet Infect Dis; 2021 Feb; 21(2):e26-e35. PubMed ID: 33125914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions.
    Abulsoud AI; El-Husseiny HM; El-Husseiny AA; El-Mahdy HA; Ismail A; Elkhawaga SY; Khidr EG; Fathi D; Mady EA; Najda A; Algahtani M; Theyab A; Alsharif KF; Albrakati A; Bayram R; Abdel-Daim MM; Doghish AS
    Biomed Pharmacother; 2023 Jan; 157():113977. PubMed ID: 36370519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 Variants, Vaccines, and Host Immunity.
    Mistry P; Barmania F; Mellet J; Peta K; Strydom A; Viljoen IM; James W; Gordon S; Pepper MS
    Front Immunol; 2021; 12():809244. PubMed ID: 35046961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.